The company experienced highly volatile revenues ranging from $4.7M to $16.5M quarterly, with no sustained positive operating income, leading to continuous net losses across all recent periods. Cost structures remain weighted toward high R&D and SG&A expenses.

Revenue growth has been inconsistent, showing an erratic pattern likely driven by order flows and delivery cycles rather than steady organic expansion. The recent quarter's revenue was substantially below estimates, indicating possible operational or demand challenges.

Gross margins varied dramatically, swinging from negative levels (-50% in some quarters) to modest positive percentages (~15%), reflecting inefficiencies in production scaling and pricing pressures. Operating losses consistently eclipse any gross profit gains.

Earnings quality is weak, with repeated substantial net losses driven by operating deficits and occasional non-recurring positives that are insufficient to offset underlying core losses. The negative EBITDA and operating income ratios confirm fundamental operational challenges.

Year-over-year revenue growth showed sporadic increases in some quarters but lacks a sustained upward trajectory; for example, Q2 2026 revenue of $4.74M declined 57.8% from Q1 2026's $11.23M. Full year 2025 revenues increased modestly versus 2024 but with great volatility between quarters.

EPS remains highly negative, fluctuating between -$0.55 and positive $0.22 in only one quarter, reflecting an overall worsening loss trajectory with only unsustainable short-term improvements.

Growth is driven primarily by new product rollouts and expanding commercial customer acquisition, but the lack of scale and persistent losses highlight the early-stage nature of growth.

Growth is fragile and likely driven by episodic large orders rather than consistent market expansion or stable organic demand, suggesting low sustainability at current scale.

Gross margins improved notably in some quarters, reaching ~38.6% in Q1 2026 before plunging to ~12.1% in Q2 2026. Operating margins remain deeply negative (around -168% recently), reflecting disproportionate SG&A and R&D expenses relative to revenue.

ROE and ROA metrics are negative and deteriorating consistent with ongoing net losses, indicating poor capital efficiency and lack of profitability.

Margins are currently unsustainable with no clear trajectory toward profitability in the near term given production inefficiencies and heavy overheads.